Derivation of Mesenchymal Stromal Cells from Ovine Umbilical Cord Wharton's Jelly

被引:1
作者
Carreras-Sanchez, Irene [1 ,2 ]
Lopez-Fernandez, Alba [1 ,2 ]
Rojas-Marquez, Raquel [1 ,2 ]
Velez, Roberto [2 ]
Aguirre, Marius [2 ]
Vives, Joaquim [1 ,2 ,3 ]
机构
[1] Banc Sang & Teixits, Serv Terapia Cellular, Edifici Dr Freder Duran i Jorda, Barcelona, Spain
[2] Univ Autnoma Barcelona, Vall dHebron Res Inst VHIR, Musculoskeletal Tissue Engn Grp, Barcelona, Spain
[3] Univ Autnoma Barcelona, Dept Med, Barcelona, Spain
来源
CURRENT PROTOCOLS | 2021年 / 1卷 / 01期
关键词
derivation; multipotent mesenchymal stromal cells; non-clinical development; preclinical animal model; regenerative medicine; sheep; stem cell culture; translational medicine; umbilical cord; Wharton's jelly; PLGA SCAFFOLDS; INTERNATIONAL-SOCIETY; ARTICULAR-CARTILAGE; MODEL;
D O I
10.1002/cpz1.18
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The methods described herein allow for the isolation and expansion of fibroblastic-like ovine Wharton's jelly-derived mesenchymal stromal cells (oWJ-MSC) that, similarly to their human counterparts, adhere to standard plastic surfaces in culture; show a mesenchymal profile for specific surface antigens (i.e., positive for CD44 and CD166); and lack expression of endothelial (CD31) and hematopoietic (CD45) markers as well as major histocompatibility complex (MHC) class-II. Homogeneous cell cultures result from a two-phase bioprocess design that starts with the isolation of mesenchymal stromal cells (MSC) from the Wharton's jelly of ovine umbilical cords up to a first step of cryopreservation. The second phase allows for further expansion of ovine WJ-MSC up to sufficient numbers for further studies. Overall, this methodology encompasses a 2-week bioprocess design that encompasses two cell culture passages ensuring sufficient cells for the generation of a Master Cell Bank. Further thawing and scale expansion results in large quantities of oWJ-MSC that can be readily used in proof of efficacy and safety studies in the preclinical development stage of the development of cell-based medicines. (c) 2021 Wiley Periodicals LLC.
引用
收藏
页数:18
相关论文
共 22 条
[1]   Mesenchymal stem cells: Cell therapy and regeneration potential [J].
Brown, Christina ;
McKee, Christina ;
Bakshi, Shreeya ;
Walker, Keegan ;
Hakman, Eryk ;
Halassy, Sophia ;
Svinarich, David ;
Dodds, Robert ;
Govind, Chhabi K. ;
Chaudhry, G. Rasul .
JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE, 2019, 13 (09) :1738-1755
[2]   Cartilage resurfacing potential of PLGA scaffolds loaded with autologous cells from cartilage, fat, and bone marrow in an ovine model of osteochondral focal defect [J].
Caminal, M. ;
Peris, D. ;
Fonseca, C. ;
Barrachina, J. ;
Codina, D. ;
Rabanal, R. M. ;
Moll, X. ;
Morist, A. ;
Garcia, F. ;
Cairo, J. J. ;
Godia, F. ;
Pla, A. ;
Vives, J. .
CYTOTECHNOLOGY, 2016, 68 (04) :907-919
[3]   Transitory improvement of articular cartilage characteristics after implantation of polylactide:polyglycolic acid (PLGA) scaffolds seeded with autologous mesenchymal stromal cells in a sheep model of critical-sized chondral defect [J].
Caminal, M. ;
Moll, X. ;
Codina, D. ;
Rabanal, R. M. ;
Morist, A. ;
Barrachina, J. ;
Garcia, F. ;
Pla, A. ;
Vives, J. .
BIOTECHNOLOGY LETTERS, 2014, 36 (10) :2143-2153
[4]   Use of a chronic model of articular cartilage and meniscal injury for the assessment of long-term effects after autologous mesenchymal stromal cell treatment in sheep [J].
Caminal, Marta ;
Fonseca, Carla ;
Peris, David ;
Moll, Xavier ;
Rabanal, Rosa M. ;
Barrachina, Josep ;
Codina, David ;
Garcia, Felix ;
Cairo, Jordi J. ;
Godia, Francesc ;
Pla, Arnau ;
Vives, Joaquim .
NEW BIOTECHNOLOGY, 2014, 31 (05) :492-498
[5]   Regulatory perspective on in vitro potency assays for human mesenchymal stromal cells used in immunotherapy [J].
De Wolf, Charlotte ;
Van De Bovenkamp, Marja ;
Hoefnagel, Marcel .
CYTOTHERAPY, 2017, 19 (07) :784-797
[6]   Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement [J].
Dominici, M. ;
Le Blanc, K. ;
Mueller, I. ;
Slaper-Cortenbach, I. ;
Marini, F. C. ;
Krause, D. S. ;
Deans, R. J. ;
Keating, A. ;
Prockop, D. J. ;
Horwitz, E. M. .
CYTOTHERAPY, 2006, 8 (04) :315-317
[7]   An arthroscopic approach for the treatment of osteochondral focal defects with cell-free and cell-loaded PLGA scaffolds in sheep [J].
Fonseca, C. ;
Caminal, M. ;
Peris, D. ;
Barrachina, J. ;
Fabregas, P. J. ;
Garcia, F. ;
Cairo, J. J. ;
Godia, F. ;
Pla, A. ;
Vives, J. .
CYTOTECHNOLOGY, 2014, 66 (02) :345-354
[8]   Compliance with Good Manufacturing Practice in the Assessment of Immunomodulation Potential of Clinical Grade Multipotent Mesenchymal Stromal Cells Derived from Wharton's Jelly [J].
Grau-Vorster, Marta ;
Rodriguez, Luciano ;
del Mazo-Barbara, Anna ;
Mirabel, Clementine ;
Blanco, Margarita ;
Codinach, Margarita ;
Gomez, Susana G. ;
Querol, Sergi ;
Garcia-Lopez, Joan ;
Vives, Joaquim .
CELLS, 2019, 8 (05)
[9]   Explant culture: An advantageous method for isolation of mesenchymal stem cells from human tissues [J].
Hendijani, Fatemeh .
CELL PROLIFERATION, 2017, 50 (02)
[10]   Clarification of the nomenclature for MSC: The international society for cellular therapy position statement [J].
Horwitz, EM ;
Le Blanc, K ;
Dominici, M ;
Mueller, I ;
Slaper-Cortenbach, I ;
Marini, FC ;
Deans, RJ ;
Krause, DS ;
Keating, A .
CYTOTHERAPY, 2005, 7 (05) :393-395